IMMXImmix Biopharma Inc. Common Stock
13.66USD+3.56%Mkt Cap: 972.45M $P/E: —3d ago
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Aus…